Physician profile
Brian Lee
NPI 1346583242
$35,437.12
in general payments reported to CMS, 2019-2025
14 companies · $2,873 in 2025
The $2,873 reported for 2025 was more than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $119 · 2023: $15K · 2024: $17K · 2025: $2,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,350 · Travel and Lodging: $2,329 · Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,092.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,350.00 |
| Travel and Lodging | $2,328.80 |
| Food and Beverage | $1,306.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $30,097.55 | 2023-2025 | Wegovy |
| Cook Incorporated | $2,350.00 | 2024 | Echotip Insight |
| Novo Nordisk As | $1,586.19 | 2023 | |
| Gilead Sciences, INC. | $338.86 | 2023-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.39 | 2021-2025 | Xifaxan |
| Osteomed LLC | $156.54 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $140.27 | 2025 | Iqirvo |
| Abbvie INC. | $135.99 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $121.82 | 2025 | Terlivaz |
| Histosonics, INC. | $119.59 | 2024 | |
| Madrigal Pharmaceuticals | $49.90 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $43.99 | 2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $27.19 | 2025 | Entyvio |
| Albireo Pharma, INC. | $19.84 | 2024 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.